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The aggregation of the amyloid- (A) peptide plays a pivotal role in the pathogenesis of Alzheimer’s disease, as soluble oligomers are
intimately linked to neuronal toxicity and inhibition of hippocampal long-term potentiation (LTP). In the C-terminal region of A there
are three consecutive GxxxG dimerization motifs, which we could previously demonstrate to play a critical role in the generation of A.
Here, we show that glycine 33 (G33) of the central GxxxG interaction motif within the hydrophobic A sequence is important for the
aggregation dynamics of the peptide. A peptides with alanine or isoleucine substitutions of G33 displayed an increased propensity to
form higher oligomers, which we could attribute to conformational changes. Importantly, the oligomers of G33 variants were much less
toxic than A42 wild type (WT), in vitro and in vivo. Also, whereas A42 WT is known to inhibit LTP, A42 G33 variants had lost the
potential to inhibit LTP. Our findings reveal that conformational changes induced by G33 substitutions unlink toxicity and oligomeriza-
tion ofA on themolecular level and suggest that G33 is the key amino acid in the toxic activity of A. Thus, a specific toxic conformation
of A exists, which represents a promising target for therapeutic interventions.
Introduction
The amyloid- (A) precursor protein (APP) is first cleaved by
the -site APP-cleaving enzyme and sequentially processed by
the -secretase complex to generate A peptides of varying
length (Qi-Takahara et al., 2005; Zhao et al., 2005). Especially
A42molecules represent themain culprits in the pathogenesis of
Alzheimer’s disease (AD) (Younkin, 1998) as they were hypoth-
esized to impair synaptic function and initiate neuronal degener-
ation (Simmons et al., 1994; Gong et al., 2003; Hsieh et al., 2006;
Shankar et al., 2007). Soluble oligomers of amyloidogenic pro-
teins are believed to be generically toxic; however, the precise
biochemicalmechanisms of toxicity are poorly understood (Buc-
ciantini et al., 2002; Kayed et al., 2003). The pathogenic effects of
A are ascribed to the hydrophobic C-terminal stretch of 14 aa
that is thought to be the seed for aggregation (Jarrett and Lans-
bury, 1993). Within this region, three repeat GxxxG motifs en-
compassing A residues G25 to G37 promote A42 aggregation
independent from the identity of the hydrophobic residues in the
x-positions (Kim and Hecht, 2006).
The glycines of the central GxxxG motif (see Fig. 1A) were
discovered as key amino acids that stabilize the association of the
-helices of APP transmembrane dimers (Munter et al., 2007).
The residues G29 and G33 of the helix interface affect the gener-
ation of A by modulating -secretase complex activity (Munter
et al., 2007; Kienlen-Campard et al., 2008).
In A peptides, the GxxxG motif has a different role with a
major impact on aggregation (Liu et al., 2005; Sato et al., 2006).
Substitution of G33 or G37 to leucines prevented A40 fibrilliza-
tion and destabilized the fibril structure by disrupting the
glycine-zipper-packing interface (Kim et al., 2005; Sato et al.,
2006). Similarly, glycine to leucine substitutions of synthetic pep-
tides were described to decrease the level of dimers and trimers in
solution and caused a reduced toxicity as well as a reduced avidity
to bind lipidmembranes (Hung et al., 2008). A gradually decreas-
ing cellular toxicity compared with the wild-type form was sug-
gested to depend on membrane permeabilization of peptides
with nonconservative glycine to leucine substitutions in the order
G29LG33LG37L (Kim et al., 2005).
In this study, we show that G33 represents the critical residue
for the assembly of A42 into neurotoxic aggregates by using
individual glycine substitutions to alanine or to isoleucine. Un-
like A42 wild-type (WT) peptides, substitutions of G33 of the
central GxxxG motif promoted rapid oligomerization through a
conformational change. Furthermore, treatment of neuronal cul-
tures with natively purified oligomers and the expression of the
different Amutants in theDrosophila melanogaster eye demon-
strated that G33 is the critical residue that mediates toxicity in
vitro and in vivo. Although A42 WT potently inhibits long-term
potentiation (LTP), oligomers derived from A42 G33 substitu-
tion peptides are unable to impair synaptic plasticity. Thus, tox-
icity of A is not a simple effect of oligomerization but a conse-
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quence of a G33-driven conformation rendering A oligomers
toxic.
Materials andMethods
Peptides. Peptides were synthesized as described previously (Beyermann
et al., 1996; Kaden et al., 2008) and verified by matrix-associated laser
desorption ionization-mass spectrometry (MALDI-MS;Ultraflex-IITOF/TOF,
Bruker Daltonics). Briefly, peptides were synthesized at automated synthesizer
(ABI 433a; Applied Biosystems) on Trt-Tentagel resin [Rapp-Polymere (0.25
mmol/g,0.5g)usingN-(9-fluorenyl)methoxycarbonyl(Fmoc)-strategy(double
couplings with 9 equivalents of Fmoc-aa/2-(1H-benzotriazole-1-yl)-1,1,3,3-
tetra-methyluronium hexafluorophosphate/6 equivalents of N,N-diisopropyl-
ethylamine]. After final cleavage and deprotection using trifluoroacetic acid/
H2O (9/1), crude peptides were purified by preparative RP-HPLC to give final
products of 95%purity according toHPLCanalysis (detector 220nm).Tomo-
nomerize synthetic A before size-exclusion chromatography (SEC), peptides
weredissolvedin98%formicacidyieldinganaverageratioofmonomers:dimer-
s:trimers of 55:30:15 (Roher et al., 1996). After immediate evaporation of the
solvent, peptides were dissolved to 1 mg/ml in 0.1% ammonia in water
(Schmecheletal.,2003).FordetectionofApeptidesbyWesternblot,weadded
4 sample buffer to the samples and electrophoresed untreated or for 3min at
95°C heated samples on 10–20% Tris-tricine gels (Anamed) according to the
manufacturer’s instructions.Proteinswere transferredon0.2mnitrocellulose,
andAwasdetectedbyWesternblotanalysis after incubationof the filterwith2
g/mlW0-2 antibody (The Genetics Company). Different batches of A pep-
tides were used to exclude individual differences which were not observed
throughout all studies.
SEC. For size-exclusion chromatography, a
Superdex 75 (10/30HR) column (GE Health-
care) was used. Aliquots of 0.5 to 1mg synthetic
peptide prepared as previously described (Ro-
her et al., 1996; Schmechel et al., 2003) were
loaded, and 1 ml fractions were eluted with 1
PBS (137 mM NaCl, 2.7 mM KCl, 10 mM
Na2HPO4, 2 mM KH2PO4) at a flow rate of 0.5
ml/min. Peptide concentrations were deter-
mined by BCA assay. The collected fractions
were immediately used for subsequent experi-
ments. The aggregation states of oligomers, sep-
arated under native conditions, were further
analyzed by SDS-PAGE under denaturing and
reducing conditions byWestern blot studies us-
ing the W0-2 antibody (The Genetics
Company).
Limited proteolysis. Peptides were dissolved
in 25 mM ammonium bicarbonate, pH 7.5 at a
concentration of 20 g/ml. The tryptic digest
was performed at 37°C using an enzyme–sub-
strate ratio of 1:500 trypsin (Roche) for up to
3 h. Fragments were identified by MALDI-MS
(Ultraflex-II TOF/TOF; Bruker Daltonics) with
sinapinic acid as matrix.
Modeling. The structure of the A42 WT tet-
ramer and variant peptides weremodeled using
the nuclear magnetic resonance structure of
A1–42 fibrils (pdb-entry: 2beg) as a template
(Lu¨hrs et al., 2005). All peptides were energeti-
cally minimized with help of the GROMOS
43B1 force field to avoid distorted geometries
(Christen et al., 2005). Electrostatic surface po-
tentials were calculated using the program
APBS (adaptive Poisson–Boltzman solver)
(Sanner et al., 1996) with nonlinear Poisson–
Boltzmann equation and contoured at9kT/e.
Toxicity of A42 on neuroblastoma cells. SH-
SY5Y cells were routinely cultured in DMEM/
Ham’s-F12 medium (PAA) supplemented with
10% (v/v) bovine calf serum, 2 mM glutamine,
0.1 mM nonessential amino acids, 100 U/ml
penicillin and 10 g streptomycin, and 0.5 mM sodium pyruvate in a 5%
CO2-humidified atmosphere at 37°C. After 48 h, medium was replaced
by medium containing freshly dissolved peptides or SEC fractions and
incubated for 12 h. Reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) was used to monitor A toxicity.
MTT stock solution (5 mg/ml) was diluted 1:10 and incubated for an-
other 1–2 h. Cells were lysed with DMSO, and the absorbance of blue
formazan at 562 nmwasmeasured using an automaticmicroplate reader.
In addition, toxicity was analyzed using 3-(4,5-dimethylthiazol-2-yl)-5-
3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)
assay (Promega), according to the manufacturer’s instructions.
Toxicity of A42 on primary hippocampal neurons. Hippocampi of
postnatal day 0 (P0)–P1 Wistar rat pups were dissociated with papain
and cultured in neurobasal Amedium supplemented with 2%B27, 2mM
glutamax, and 0.2% penicillin/streptomycin on glia cell feeder layers.
After 10 d in vitro, neuronal cultures were treated with A1–42 freshly
dissolved or with SEC fractions for another 48 h. Neuronal viability was
detected using the MultiTox-Fluor Multiplex Cytotoxicity assay (Pro-
mega), performed according to manufacturer’s instructions.
Drosophila melanogaster transformation and eye structure analysis.
The A42-coding sequence preceded by the signal-peptide sequence of
DrosophilaHedgehog proteinwas ligated into the P-element transforma-
tion vector pUAST yielding the construct pUAST–SP–A42 WT. Muta-
tions were generated using the quick-change mutagenesis technique.
pUAST–SP–A42, pUAST–SP–A42 G29/33A, and pUAST–SP–A42
G33I constructs were used to generate transgenic flies with standard
P-element-mediated transformation. Transgenic flies harboring UAS–
Figure 1. Single amino acid exchanges within the GxxxGmotif of A42 modulate oligomerization. A, Amino acid sequence of
A1–42 with the glycines of the three consecutive GxxxGmotifs numbered. The amino acid substitutions of the analyzed central
GxxxG motif are in bold. B–F, SEC and Western blot analysis of freshly dissolved synthetic A42 peptides. B, A42 WT peptides
preferentially form tetramers but also lower and higher oligomers. C, A42 G29A peptides preferentially form tetramers and only
few other oligomers. D, A42 G33A variant peptide mainly form higher oligomers but also low-n oligomers. E, A42 G33I
substitution peptides almost exclusively formhigher oligomers but hardly anymonomers to decamers. F, Size separation of A42
G29/33A yields high amounts of tetramers but also large amounts of high oligomers. Representative chromatograms of at least
three independentmeasurements are shown.Western blots of freshly dissolved synthetic A aggregates (Load) (compare figure
insets) in the presence of SDS reveal monomers and high-n oligomers for all peptides. Compared with A42 WT, G29A, and
G29/33A, solely the amount of low-n oligomers of A42 G33 substitution peptides is reduced.
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A42WT or UAS–A42 G29/33A or UAS–A42
G33I were crossed with flies containing GMR–
Gal4 (glass multimer reporter) to achieve eye-
specific expression of A peptides. Five-day-
old flies were collected and analyzed. Scanning
electron microscopy pictures were taken with a
JEOL JSM-6360LV microscope. Eye sections
were analyzed as described previously (Basler
and Hafen, 1988).
Electrophysiology. For electrophysiological
measurements, hippocampal slices from 3- to
6-week-old Wistar rats were prepared and
stored in oxygenated artificial CSF (ACSF; 119
mM NaCl, 1 mM NaH2PO4, 10 mM glucose, 1.3
mM MgSO4, 2.5 mM CaCl2, 2.5 mM KCl, 26 mM
NaHCO3). Field EPSPs (fEPSPs) were recorded
in stratum radiatum of area CA1 and evoked by
Schaffer collateral stimulation with ACSF-filled
electrodes. For the measurement of two inde-
pendent pathways, two stimulating electrodes
were positioned in parallel to each other. Base-
line responses were collected using test pulses
that yield 30–40% of the maximal fEPSP slope.
Stable baseline response was measured for at
least 10 min, slices were supplied with 500 nM
peptide 20 min before tetanization. LTP was
induced by theta-burst stimulation (TBS) of
one of the two pathways. The intertheta burst
stimulation interval was 20 s, and four TBSs
were applied to induce LTP. TBS consisted of 10 bursts delivered at 5 Hz.
Each burst consisted of four pulses delivered at 100Hz. After TBS, fEPSPs
were observed for 30 min. The amount of LTP was described as percent-
age changes of fEPSP slopes after TBS normalized to baseline values with
an additional subtraction of the second, unstimulated pathway. Slopes
were analyzed using IGOR (Wavemetrics).
Results
Substitution of amino acid residue G33 of the GxxxGmotif
provokes A aggregation
We investigated the role of glycine residues within the GxxxG
motif in A oligomerization by SEC using synthetic A42 pep-
tides with substitutions of G29 and G33 to alanine or isoleucine
(Fig. 1A). We found similar elution patterns for A42 WT (Fig.
1B) and A42 G29A (Fig. 1C). The fractions primarily yielded
tetramers and hexamers and only minor amounts of oligomers
corresponding to apparent molecular masses of 16- to 20-mers,
dimers, and monomers (Fig. 1B,C). In contrast, single amino
acid substitutions at position G33 resulted in a dramatic increase
in the relative amount of higher oligomers (16- to 20-mers) at the
expense of lower oligomers (2- to 4-mers) (Fig. 1D,E), depend-
ing on the increasing hydrophobicity of the substituted amino
acid at this position in the order WTG33AG33I. Finally, the
double substitution A42 G29/33A yielded an intermediate oli-
gomerization with similar amounts of 16- to 20-mers and 4- to
6-mers (Fig. 1F). Thus, G33 plays a critical role in early aggrega-
tion of A42 into higher oligomers, whereas G29 has no effects.
Subsequently, the oligomeric distribution was confirmed by
Western blot analysis of the respective SEC fractions (supple-
mental Fig. S1, available at www.jneurosci.org as supplemental
material), although the presence of SDS caused a partial dissoci-
ation of the aggregates into monomers. Thus, using different
techniques, we found that G33 substitutions rather promoted
than retarded the aggregation process, implying that G33 is a key
residue during the early steps of oligomerization.
Aggregation characteristics of A42 G33 variants are
determined by conformational changes
To examine whether the observed differences in aggregation be-
havior are attributable to differences in oligomer folding, we used
limited trypsin proteolysis coupled tomass spectrometry (Fig. 2).
Proteolysis leads to the production of fragments A1–16 (data not
shown), A1–28, and the corresponding C-terminal products im-
plying that this region is highly flexible and easily accessible for
trypsin (Fig. 2). The representative spectra of all peptides tested
reveal that after a 3 h digest with trypsin, the fragment A17–42
was generated from A42 (Fig. 2A). At this time point, the gen-
eration of the fragment A1–28 was impaired for the G33 single
substitution peptides compared with the three other peptides. In
a time course analysis of the proteolysis, the ratio of peak areas of
fragment A1–28 to uncleaved A42 was calculated. In case of
A42 G29A and A42 G29/33A, we observed a time-dependent
generation of the fragment A1–28 during the 3 h period of diges-
tion with an increased ratio of A1–28/A42 compared with A42
WT (Fig. 2B). In contrast, A42 G33A and A42 G33I peptides
remained virtually uncleaved at position K28 (Fig. 2C). Thus,
A42G29A andG29/33Apeptides seemingly possess amore open
conformation comparedwithA42WT.Whereas single anddou-
ble substitutions including G29 promote a conformation that is
better accessible to trypsin, the single substitutions of G33 to
alanine or isoleucine rather induce amore tightly packed confor-
mation, thereby masking K28. As a conclusion, the different ac-
cessibility of K28 to trypsin indicates that the G33 substitution
further enhances the stability of the folding nucleus around this
lysine residue within the turn region (Lazo et al., 2005; Grant et
al., 2007). Hence, G33 can be regarded as a key residue to drive
the intermolecular peptide interactions, which is necessary for
higher-order peptide assembly.
Conformational changes of A42 G33 variants are induced by
increased hydrophobicity
In a computational analysis of A42 WT and substitution pep-
tides, the modeling illustrates that, in contrast to theWT peptide
Figure 2. Amino acid exchanges at position G29 and G33 affect accessibility of A K28. A, MALDI-MS spectra of 3 h tryptic
digests yield the followingmasspeaks (inDa forWT):A1–42, 4512.3;A1–28, 3261.4;A17–42, 2576.3.Note that themass shifts
are because of amino acid substitutions.B, Generation of A fragment 1–28 by limited tryptic digestion of A42WT, A42 G29A,
and A42 G29/33A and (C) A42 WT, A42 G33A, and A42 G33I. The amount of fragment 1–28 was calculated as the ratio
(A1–28/A1–42) of ion peak areas of MALDI-MS spectra recorded at different time points. Note the different scale bars in B and C.
Compared with A42 WT, a rapid formation of high amounts of A1–28 is observed when G29 is substituted but hardly any
cleavage of trypsin at position K28 when G33 is exchanged. Representative spectra and evaluation of at least three independent
measurements are shown.
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(Fig. 3A), a continuous hydrophobic surface is formed by G33
substitution (Fig. 3C). This effect is even more pronounced for
the G33I substitution (Fig. 3D).When the peptides assemble into
-sheets, the hydrophobic side chains of G33I and G33A are
effectively shielded from the polarmilieu (Fig. 3C,D; supplemen-
tal Fig. S2, available at www.jneurosci.org as supplemental mate-
rial). Simultaneously, the hydrophobic side chains of the neigh-
boring hydrophobic residues I31 and/or M35 are also buried,
which might explain why A42 G33A and G33I peptides are
tightly packed, masking K28 and tend to form higher oligomers
comparedwithA42WT(supplemental Fig. S2, available atwww.
jneurosci.org as supplemental material). In contrast, G29 is po-
sitioned within the turn structure of A42, and its side chain is
entirely exposed, offering an explanation why the G29A substitu-
tion has only a weak effect on oligomerization and why it can be
cleaved more effectively by trypsin (Figs. 1, 2, 3B; supplemental
Fig. S2, available at www.jneurosci.org as supplemental mate-
rial). Interestingly, the double substitution peptide A42 G29/
33A yields an intermediate state (Fig. 3E; supplemental Fig. S2,
available at www.jneurosci.org as supplemental material), also in
terms of oligomerization (Fig. 1F), which is attributable to the
change in the turn structure induced by G29A and the continu-
ous hydrophobic surface, which can be allocated to the G33A
substitution. This suggests a close interplay of G29 andG33 of the
central GxxxG motif that plays a crucial role in the folding of
A42.
A toxicity is determined by G33
To examine the toxic properties of A42 WT or the substitution
peptides, we tested the effects of a freshly dissolved mixture or
defined SEC fractions on the cell death of
human neuroblastoma SH-SY5Y cells us-
ing MTT and MTS assays and on primary
neurons using the MultiTox assay (Figs. 4,
5). Treatment of SH-SY5Y cells with equal
aliquots of crude A42WT peptide [corre-
sponding to “Load” fractions of SEC (Fig.
1B)] reduced the number of living cells by
59  7% compared with untreated cells
(Fig. 4A). When we analyzed different de-
fined oligomeric SEC fractions, tetramers
of A42 WT exhibited the highest toxicity.
Interestingly, toxicity negatively corre-
lated with samples containing oligomers
higher than tetramers (Fig. 4A). Because
of the relatively limited power of separa-
tion by SEC and because of broad fractions
collected, we observed toxicity in samples
that mainly contained monomers but
most likely also contaminating dimers
(supplemental Fig. S1, available at www.
jneurosci.org as supplemental material).
On primary cultures of hippocampal
neurons, fractions containing low-n A42
WToligomers were found to bemost toxic
(Fig. 5A). Similar to theA42WTpeptides,
tetramers of A42 G29A induced highest
toxic effects on SH-SY5Y cells and on pri-
mary neurons. Toxicity was stepwise de-
clining when oligomerization proceeded
(Figs. 4B, 5B). In sharp contrast, in none of
the fractions containing A42 G33A or
A42G33I a significant level of toxicitywas
detected, neither on neuroblastoma cells nor on primary neurons
(Figs. 4C,D, 5C,D). Solely, A42 G29/33A demonstrated an inter-
mediate toxicity compared with A42 WT and A42 G33 single
substitution peptides (Figs. 4, 5A,D,E).
In an additional approach, we usedDrosophilamelanogaster flies
where A toxicity is evident from a range of eye abnormalities
(Finelli et al., 2004), and theextentof cell deathcanbedeterminedby
visual inspection of the eye structure (Basler and Hafen, 1988).
Therefore, to further investigate the toxicity ofmutationswithin the
central GxxxG motif in vivo, we generated and selected strains ex-
pressing equal amounts of secreted A42 WT, A42 G29/33A, or
A42 G33I in the eye (Fig. 6; supplemental Fig. S3, available at www.
jneurosci.org as supplemental material). Compared with nontrans-
genic control animals, analysis of eye sections from transgenic flies
demonstrated thatA42G33I induces a verymild toxic effect, which
is evident from aweak distortion in eyemorphology (Fig. 6A,D). In
contrast,A42WTorA42G29/33Amutants both caused severe eye
degeneration (Fig. 6B,C). Toxicity can be estimated as a ratio of
rhabdomeres to ommatidia, which we found significantly reduced
for A42 WT and A42 G29/33A mutants compared with control
animals (Fig. 6E). Conversely, A42 G33I flies exhibited a ratio of
rhabdomeres to ommatidia that was not significantly different from
the control flies (Fig. 6E), although the visual inspection indicates a
slight change in morphology. Additionally, whereas treatment with
the double substitution peptide A42 G29/33A revealed an interme-
diate characteristic of toxicity on the two different cell culture sys-
temsanalyzed, toxicity in theDrosophilamodel of theA42G29/33A
mutant strongly resembles the situation in theAWTexpressing fly
strain. TheGMRregulatory region is known to drive expression of a
linked gene from late larval stage throughout adult life. Most likely
Figure 3. Single amino acid exchange at position G33 modifies conformation of A42 oligomers. Amino acid sequences and
computational models of A42 WT (A), A42 G29A (B), A42 G33A (C), A42 G33I (D), and A42 G29/33A (E) monomers and
tetramers. Glycine residues 25, 29, 33, and 37 of the three consecutive GxxxGmotifs are numbered, and substitutions at position
G29 and G33 are in bold (sequence) andwith arrows (monomermodel). Negatively charged surfaces in red, positively charged in
blue (Baker et al., 2001). Increase in hydrophobicity at G33 leads to stabilization of the folding core, provokes-sheet conforma-
tion and increases oligomerization.
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theobserved eyephenotypeshave adevelop-
mental as well as a continued expression
component, and the toxic effect of A42
G29/33A would reflect an in vivo situation
that differs from the effects of synthetic pep-
tides on mature SH-SY5Y cells or primary
neurons.
A inhibition of LTP is determined
by G33
Hippocampal LTP is a form of synaptic
plasticity thought to correlate with learn-
ing and memory formation on a cellular
level. Maintenance of hippocampal LTP is
inhibited by synthetic and natural soluble
A oligomers, principally dimers and
low-n oligomers (Walsh et al., 2002;Wang
et al., 2002; Klyubin et al., 2005; Cheon et
al., 2007; Klyubin et al., 2008). LTP is also
inhibited by A peptides of shorter se-
quence with a biological activity being at-
tributed to the region encompassing resi-
dues 25–35 (Freir et al., 2003; Gengler et
al., 2007) containing G29 and G33 of the
A GxxxG motif. To test whether G33 is
crucial for the abolishment of LTP by
A42, we assessed the effect of A42 GxxxG
substitution peptides on theta burst-
induced LTP in the CA1 region of rat hip-
pocampal slices. As expected, A42WT in-
hibited LTP compared with control
conditions (Fig. 7A,D). In contrast, the
G33I substitution of A42 peptides did not
inhibit LTP but was comparable with con-
trol slices, when a solution of freshly dis-
solved A42 G33I peptides was tested
(control vs A42 G33I) (Fig. 7B,D). Since
A42 G33I only yielded very minor
amounts of tetramers (Fig. 1E), we tested
SEC fractions containing A42 G33A tet-
ramers on LTP inhibition. Unlike A42
WT which inhibited LTP, A42 G33I and
tetramers formed by A42 G33A (Fig.
7C,D) substitution peptides had no effect
on LTP. Thus, our results reveal that the
aggregation of A42 into tetramers does not necessarily inhibit
LTP.
Discussion
The progressive neurodegenerative symptoms of AD are at the
earliest evident by cumulative deficits in learning andmemory. In
vivo, this loss in cognitive functions correlates with a decrease in
synaptic markers and appears long before A plaque deposition
is detected (Hsia et al., 1999; Moechars et al., 1999; Mucke et al.,
2000; Spires et al., 2005). Despite the evidence that low-n A
oligomers can interfere with normal synaptic physiology
(Podlisny et al., 1995; Shankar et al., 2008), it remains an unan-
swered question if A oligomers contribute to the cognitive de-
cline in AD. Little is known about the factors that regulate the
generation of toxic A aggregates in the aging brain. The produc-
tion of soluble oligomeric intermediates of A was early discov-
ered to be responsible for A toxicity and LTP inhibition
(Yankner et al., 1989; Stern et al., 2004), whereas larger A fibrils
were inert (Podlisny et al., 1995; Roher et al., 1996, 2000;McLean
et al., 1999; Walsh et al., 2002; Roychaudhuri et al., 2009). Nev-
ertheless, amyloid plaque fibrils were recently shown to represent
potentially major sources of soluble toxic A aggregates when
they are activated by exposure to biological lipids (Martins et al.,
2008). Amyloid fibrils once resolubilized to oligomers thus be-
came highly toxic (Martins et al., 2008).
Although it has been demonstrated that A oligomerization is
a key step in the toxicity, we provide evidence that a single amino
acid residue (G33) of theGxxxGmotif is a key residue influencing
toxicity of A42 enabling now to better define the origin of
toxicity.
Earlier reports have shown that nonconservative substitutions
of glycines to leucines effect toxic behavior in vitro of a crude
mixture of A42 peptides (Kim et al., 2005; Hung et al., 2008). In
this study, we have determined by conservative and nonconser-
vative substitutions of the GxxxG motif that G33 of A is the
critical residue for peptide aggregation, in vivo toxicity in neuro-
Figure 4. A42 WT but not A42 G33 substitution peptides are toxic to neuroblastoma cells. For all measurements, equal
amounts of freshly dissolved peptides (Load) or of oligomer fractions after SEC and as determined by the BCA assays were used.
Toxicity is described as percentage of cell death comparedwith untreated control cells (n 4–8 SEM).A, A42WT exhibits a
maximal toxicity. Toxicity increases from monomeric to tetrameric forms and then gradually decreases for higher oligomers. B,
A42 G29A reveals toxicity similar to theWT peptide. C,D, Both A42 G33A (C) and A42 G33I (D) lack any significant toxicity. E,
A42 G29/33A occupies an intermediate toxicity for the unseparated peptide. The toxicity of the A42 G29/33A SEC fractions is
similar to theWT for 4-mer, 10-mer, and20-mer and in the rangeofA42G33I in caseof themonomer, dimer, 6-mer, and16-mer.
A one-way ANOVA using Dunnett’s multiple comparison test comparing peptides with untreated control was performed (*p
0.01, **p 0.001, ***p 0.0001).
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nal cultures and in the Drosophila melanogaster eye and the inhi-
bition of LTP. Furthermore, we have investigated in detail the
importance of the GxxxG motif for A aggregation and toxicity
and the interrelationship between toxicity and LTP inhibition as
well as conformational characteristics of A oligomers by using
limited tryptic proteolysis in combination with computational
modeling.
Early oligomerization has been regarded as the most impor-
tant prerequisite for A peptides to gain toxicity. In the case of
A42 G33 substitution peptides, oligomerization was neither suf-
ficient to induce toxic effects nor to inhibit LTP, and therefore,
oligomer formation and toxicity of A are unlinked. Our results
obtained by SEC and Western blot analysis exhibited that A42
G33 substitution peptides immediately formed higher oligomers
compared with A42WT. Data achieved from limited proteolysis
emphasizes that G33 variants have a more compact folding core.
These results were supported by computational modeling, which
indicates that the effective shielding of hydrophobic side chains
from the polarmilieu promotes a tight folding of the peptides and
evenmore their formation into higher oli-
gomers as analyzed by SEC. Consistently,
only residual amounts of dimers and tet-
ramers generated under native conditions
and no SDS-resistant low-n oligomers
could be detected in case of G33I. Since the
G29A substitution in the turn region of A
is entirely exposed to the solvent, model-
ing data suggested that the core is destabi-
lized without affecting the aggregation be-
havior. The folding nucleus of G29A is less
compact, and the accessibility for trypsin
at the cleavage site K28 as part of the core is
increased. When combining both substi-
tutions to A42 G29/33A, an intermediate
behavior was observed in terms of peptide
oligomerization with an intermediate dis-
tribution between low-n and high-n oli-
gomers. Thus, a specific conformation is
maintained by the GxxxG sequence in the
C-terminal half of A, which is required
for its toxicity. This is in agreement with
toxicity studies using G33L substitutions
of A that showed a reduced formation of
dimers and trimers by mass spectrometry
analysis (Hung et al., 2008). Biophysical
characterization of the so-called GSL (gly-
cine substitution to leucine) peptides re-
vealed an increased rate of fibril formation
and a reduced ability to bind to lipidmem-
branes (Hung et al., 2008). Also, the in
vitro toxicity of GSL substitutions peptides
was suggested to depend on their ability to
disrupt membranes (Kim et al., 2005).
In accordance with other studies where
soluble lower-n oligomers were identified
to be responsible for A toxicity (Yankner
et al., 1989; Stern et al., 2004; Shankar et
al., 2008), we depicted A42 WT tetramers
as the most toxic form for neuroblastoma
cells and for primary hippocampal neu-
rons. The extent of cell loss decreased with
increasing grade of oligomerization of
A42 WT or A42 G29A peptides. In sharp
contrast, none of the peptides A42 G33A or G33I were toxic,
neither to neuroblastoma cells nor to primary hippocampal neu-
rons. Although A42WT tetramers were highly toxic, the tetram-
ers of A42 G33 variants were nontoxic and thereby provided
evidence that the aggregation of A42 peptides is uncoupled from
toxicity. Complementary to the intermediate position in its ag-
gregation behavior, the A42 G29/33A peptide revealed an in-
between toxicity of A42 WT and G33 substitutions. Although
synthetic peptides did not allow to directly assess whether cell-
derived A can have similar effects, we generated Drosophila
melanogastermodels expressing secreted A42 WT and G33 vari-
ants in the eye. The results are in agreement with the cell-culture
data insofar as Drosophila eyes expressing A42 G33I are normal
compared with A42 WT expressing flies, although the aggrega-
tion state in the eyes remains unclear.
Since diffusible oligomers of A initiate a synaptic dysfunc-
tion that is believed to be an early event in AD (Walsh et al., 2002;
Cleary et al., 2005), we performed field recordings in hippocam-
pal slices with A G33 variants to test if these peptides inhibit
Figure 5. A42WT but not A42 G33 substitution peptides are toxic to primary neurons.Measurementswere performedwith
neurons incubated with equal amounts of freshly dissolved synthetic peptides (Load) or SEC fractions. Results are expressed as
percentage of cell death. A, A42 WT (n 4–8 SEM) induces a maximal toxicity. Comparable with the data generated from
neuroblastoma cells, toxicity increases from monomeric to tetrameric forms and then gradually decreases again as the peptide
aggregates further intohigher oligomers up to20-mers.B, Similar toA42WT, the samepattern couldbeobserved forA42G29A
(n 2–8 SEM). C, D, A42 G33A (C) and A42 G33I (D) (n 4–8 SEM) cause no significant toxicity in primary neurons.
E, Toxicity of A42 G29/33A (n2–8 SEM) is similar toA42WT formonomers to tetramers and toA42 G33 variant peptides
for higher aggregates. A one-way ANOVA using Dunnett’s multiple comparison test comparing peptides with untreated control
was performed (*p 0.001, **p 0.0001).
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synaptic plasticity. Although A42 WT en-
tirely inhibited LTP,A42G33I and partic-
ularly A42 G33A tetramers showed an at-
tenuated LTP inhibition. Thus, A42 WT
impairs synaptic plasticity, whereas G33
variants are inert. This is in full agreement
with the current knowledge on A WT
toxicity and implies the existence of a mo-
lecular link between peptide toxicity and a
specific conformation of A oligomers.
In conclusion, G33 substitutions could
uncouple oligomerization from toxicity
and LTP inhibition. The nonpathogenic
effects of these substitutions can be mech-
anistically accounted for by fold stabiliza-
tion. We propose that by enhancing the
hydrophobicity at position G33 A42 ag-
gregation is alleviated, and the aggre-
gates—because of the tertiary structure
they adopt—neither impair cell viability
nor inhibit synaptic plasticity. On the
background that hydrophobic stretches in
the C-terminal half of A42 are sufficient
to promote aggregation (Kim and Hecht,
2006), our data underline the importance
of the GxxxG motif for the specific toxic
A fold. Beyond soluble oligomers that are
intermediates in the fibrillization process,
substitutions of G29, G33, and G37 of the
GxxxG motif were described as generally
destabilizing for fibril structures (Mori-
moto et al., 2004; Williams et al., 2004;
Shivaprasad andWetzel, 2006;Williams et
al., 2006).
Our results suggest the existence of dif-
ferent types of A42 strains, some causing
toxic effects and others aggregation into
oligomers without adopting toxic conformations. This hypothe-
sis is supported by the effects of A42 G29/33A oligomers, which
might represent transition forms of a mixture of toxic and non-
toxic amyloid strains. Regarding the mechanism of toxicity
caused by A, the cellular prion protein and the amyloid
precursor-like protein 1 (APLP1) were suggested as possible me-
diators of A-induced synaptic dysfunction (Laure´n et al., 2009).
APLP1 forms heterodimers with APP and is mainly present on
the cell surface (Kaden et al., 2009); it is, therefore, a strong can-
didate receptor for A oligomers.
The findings of our study now open up a new avenue to ana-
lyze the binding of nontoxic and toxic oligomers to the proposed
receptors and to unravel the mechanisms of A toxicity in more
detail to combat disease causes in AD.
References
Baker NA, Sept D, Joseph S, HolstMJ,McCammon JA (2001) Electrostatics
of nanosystems: application tomicrotubules and the ribosome. Proc Natl
Acad Sci U S A 98:10037–10041.
Basler K, Hafen E (1988) Sevenless and Drosophila eye development: a ty-
rosine kinase controls cell fate. Trends Genet 4:74–79.
Beyermann M, Fechner K, Furkert J, Krause E, Bienert M (1996) A single-
point slight alteration set as a tool for structure-activity relationship stud-
ies of ovine corticotropin releasing factor. J Med Chem 39:3324–3330.
Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, Taddei N,
Ramponi G, Dobson CM, Stefani M (2002) Inherent toxicity of aggre-
gates implies a common mechanism for protein misfolding diseases. Na-
ture 416:507–511.
Cheon M, Chang I, Mohanty S, Luheshi LM, Dobson CM, Vendruscolo M,
Favrin G (2007) Structural reorganisation and potential toxicity of oli-
gomeric species formed during the assembly of amyloid fibrils. PLoS
Comput Biol 3:1727–1738.
Christen M, Hu¨nenberger PH, Bakowies D, Baron R, Bu¨rgi R, Geerke DP,
Heinz TN,KastenholzMA,Kra¨utler V,OostenbrinkC, Peter C, Trzesniak
D, van Gunsteren WF (2005) The GROMOS software for biomolecular
simulation: GROMOS05. J Comput Chem 26:1719–1751.
Cleary JP,WalshDM,Hofmeister JJ, ShankarGM,KuskowskiMA, SelkoeDJ,
Ashe KH (2005) Natural oligomers of the amyloid-beta protein specifi-
cally disrupt cognitive function. Nat Neurosci 8:79–84.
Finelli A, Kelkar A, Song HJ, Yang H, Konsolaki M (2004) A model for
studying Alzheimer’s Abeta42-induced toxicity in Drosophila melano-
gaster. Mol Cell Neurosci 26:365–375.
Freir DB, Costello DA, Herron CE (2003) A beta 25–35-induced depression
of long-term potentiation in area CA1 in vivo and in vitro is attenuated by
verapamil. J Neurophysiol 89:3061–3069.
Gengler S, Gault VA, Harriott P, Ho¨lscher C (2007) Impairments of hip-
pocampal synaptic plasticity induced by aggregated beta-amyloid (25–35)
are dependent on stimulation-protocol and genetic background. Exp
Brain Res 179:621–630.
Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA,
Klein WL (2003) Alzheimer’s disease-affected brain: presence of oligo-
meric A beta ligands (ADDLs) suggests a molecular basis for reversible
memory loss. Proc Natl Acad Sci U S A 100:10417–10422.
GrantMA, LazoND, Lomakin A, CondronMM,Arai H, YaminG, Rigby AC,
Teplow DB (2007) Familial Alzheimer’s disease mutations alter the sta-
bility of the amyloid beta-protein monomer folding nucleus. Proc Natl
Acad Sci U S A 104:16522–16527.
Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko
Figure 6. A42WT but not A42 G33mutants are toxic in vivo in transgenic Drosophila melanogaster expressing extracellular
A42 WT or mutant peptides. For the analyses, strains of flies were selected for expressing equal amounts of A forms (supple-
mental Fig. S3, available at www.jneurosci.org as supplemental material). Analysis of A toxicity in transgenic flies by scanning
electronmicroscopy of eye structure (top) and sections (bottom).A–D, Eyes of control flies (A) and flies expressing A42 G33I (D)
show a negligible distortion compared with those expressing A42 WT (B) or A42 G29/33A (C). Scale bar, 100m. Represen-
tative pictures of at least three independent animals are shown. E, Quantification of the A-mediated toxicity by calculating the
ratio between rhabdomeres andommatidia in 3–5animals for eachgroup. BothA42WTandG29/33Aexpressing flies are highly
toxic comparedwith nontransgenic control flies, whereas A42 G33I does not cause severe eye damage. Student’s t testwas used
to compare transgenic groups with the control group (*p 0.01).
7588 • J. Neurosci., June 10, 2009 • 29(23):7582–7590 Harmeier et al. • Glycine 33 of Amyloid-
D, Malenka RC, Nicoll RA, Mucke L (1999) Plaque-independent dis-
ruption of neural circuits in Alzheimer’s diseasemousemodels. Proc Natl
Acad Sci U S A 96:3228–3233.
Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R
(2006) AMPAR removal underlies Abeta-induced synaptic depression
and dendritic spine loss. Neuron 52:831–843.
Hung LW, Ciccotosto GD, Giannakis E, TewDJ, Perez K,Masters CL, Cappai
R,Wade JD, BarnhamKJ (2008) Amyloid- peptide (A) neurotoxicity
is modulated by the rate of peptide aggregation: A dimers and trimers
correlate with neurotoxicity. J Neurosci 28:11950–11958.
Jarrett JT, Lansbury PT Jr (1993) Seeding “one-dimensional crystallization”
of amyloid: a pathogenic mechanism in Alzheimer’s disease and scrapie?
Cell 73:1055–1058.
Kaden D, Munter LM, Joshi M, Treiber C, Weise C, Bethge T, Voigt P,
Schaefer M, Beyermann M, Reif B, Multhaup G (2008) Homophilic in-
teractions of the amyloid precursor protein (APP) ectodomain are regu-
lated by the loop region and affect beta-secretase cleavage of APP. J Biol
Chem 283:7271–7279.
Kaden D, Voigt P, Munter LM, Bobowski KD, Schaefer M, Multhaup G
(2009) Subcellular localization and dimerization of APLP1 are strikingly
different from APP and APLP2. J Cell Sci 122:368–377.
Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW,
Glabe CG (2003) Common structure of soluble amyloid oligomers im-
plies common mechanism of pathogenesis. Science 300:486–489.
Kienlen-Campard P, Tasiaux B, VanHees J, LiM,Huysseune S, Sato T, Fei JZ,
Aimoto S, Courtoy PJ, Smith SO, Constantinescu SN, Octave JN (2008)
Amyloidogenic processing but not amyloid precursor protein (APP) in-
tracellular C-terminal domain production requires a precisely oriented
APP dimer assembled by transmembrane GXXXG motifs. J Biol Chem
283:7733–7744.
Kim S, Jeon TJ, Oberai A, Yang D, Schmidt JJ, Bowie JU (2005) Transmem-
brane glycine zippers: physiological and pathological roles in membrane
proteins. Proc Natl Acad Sci U S A 102:14278–14283.
Kim W, Hecht MH (2006) Generic hydrophobic residues are sufficient to
promote aggregation of the Alzheimer’s
Abeta42 peptide. Proc Natl Acad Sci U S A
103:15824–15829.
Klyubin I, Walsh DM, Lemere CA, Cullen WK,
Shankar GM, Betts V, Spooner ET, Jiang L,
Anwyl R, Selkoe DJ, Rowan MJ (2005) Amy-
loid beta protein immunotherapy neutralizes
Abeta oligomers that disrupt synaptic plastic-
ity in vivo. Nat Med 11:556–561.
Klyubin I, Betts V, Welzel AT, Blennow K, Zetter-
berg H, Wallin A, Lemere CA, Cullen WK,
Peng Y, Wisniewski T, Selkoe DJ, Anwyl R,
Walsh DM, Rowan MJ (2008) Amyloid 
protein dimer-containing human CSF dis-
rupts synaptic plasticity: prevention by sys-
temic passive immunization. J Neurosci
28:4231–4237.
Laure´n J, Gimbel DA, Nygaard HB, Gilbert JW,
Strittmatter SM (2009) Cellular prion pro-
teinmediates impairment of synaptic plasticity
by amyloid-beta oligomers. Nature
457:1128–1132.
Lazo ND, Grant MA, Condron MC, Rigby AC,
Teplow DB (2005) On the nucleation of
amyloid beta-protein monomer folding. Pro-
tein Sci 14:1581–1596.
LiuW, Crocker E, ZhangW, Elliott JI, Luy B, Li H,
Aimoto S, Smith SO (2005) Structural role of
glycine in amyloid fibrils formed from trans-
membrane alpha-helices. Biochemistry
44:3591–3597.
Lu¨hrs T, Ritter C, Adrian M, Riek-Loher D, Bohr-
mann B, Do¨beli H, Schubert D, Riek R (2005)
3D structure of Alzheimer’s amyloid-beta(1–
42) fibrils. Proc Natl Acad Sci U S A
102:17342–17347.
Martins IC, Kuperstein I, Wilkinson H, Maes E,
Vanbrabant M, Jonckheere W, Van Gelder P,
Hartmann D, D’Hooge R, De Strooper B,
Schymkowitz J, Rousseau F (2008) Lipids revert inert Abeta amyloid
fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J
27:224–233.
McLean CA, Cherny RA, Fraser FW, Fuller SJ, SmithMJ, Beyreuther K, Bush
AI, Masters CL (1999) Soluble pool of Abeta amyloid as a determinant
of severity of neurodegeneration in Alzheimer’s disease. Ann Neurol
46:860–866.
Moechars D, Dewachter I, Lorent K, Reverse´ D, Baekelandt V, Naidu A,
Tesseur I, Spittaels K, Haute CV, Checler F, Godaux E, Cordell B, Van
Leuven F (1999) Early phenotypic changes in transgenic mice that over-
express different mutants of amyloid precursor protein in brain. J Biol
Chem 274:6483–6492.
Morimoto A, Irie K, Murakami K, Masuda Y, Ohigashi H, NagaoM, Fukuda
H, Shimizu T, Shirasawa T (2004) Analysis of the secondary structure of
beta-amyloid (Abeta42) fibrils by systematic proline replacement. J Biol
Chem 279:52781–52788.
Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K,
Kholodenko D, Johnson-Wood K, McConlogue L (2000) High-level
neuronal expression of A1–42 in wild-type human amyloid protein pre-
cursor transgenicmice: synaptotoxicity without plaque formation. J Neu-
rosci 20:4050–4058.
Munter LM,Voigt P,Harmeier A, KadenD,Gottschalk KE,Weise C, Pipkorn
R, Schaefer M, Langosch D, Multhaup G (2007) GxxxG motifs within
the amyloid precursor protein transmembrane sequence are critical for
the etiology of Abeta42. EMBO J 26:1702–1712.
Podlisny MB, Ostaszewski BL, Squazzo SL, Koo EH, Rydell RE, Teplow DB,
Selkoe DJ (1995) Aggregation of secreted amyloid beta-protein into so-
dium dodecyl sulfate-stable oligomers in cell culture. J Biol Chem
270:9564–9570.
Qi-Takahara Y, Morishima-Kawashima M, Tanimura Y, Dolios G, Hirotani
N, Horikoshi Y, Kametani F, Maeda M, Saido TC, Wang R, Ihara Y
(2005) Longer forms of amyloid  protein: implications for the mecha-
nism of intramembrane cleavage by -secretase. J Neurosci 25:436–445.
Figure 7. LTP of Schaffer collateral CA1 region is inhibited by A42WT but not A42 G33 substitution peptides. LTP induction
with theta-burst stimulation ismarked by an arrow. Peptide (500 nM)waswashed-in for 20min before tetanization, nowash-out
occurred during the whole experiment. A–C represents fEPSP difference of unstimulated control pathway and stimulated path-
way. Insets show average baseline (1) and post-TBS (2) fEPSP traces with calibration bars: 10 ms, 0.2 mV. A42 peptides (closed
circles) in overlaywith controlmeasurements (open circles). IncubationwithA42WT (A) peptide leads to LTP inhibition,whereas
A42 G33I (B) does not inhibit LTP. C, Nontoxic A42 G33A tetramer peptide does not inhibit LTP.D, Quantification of 25–30min
post-tetanus of each measurement (control, n 19 SEM; A42 WT/G33I, n 11 SEM; A42 G33A, n 4 SEM). A
one-way ANOVA using Dunnett’s multiple comparison test comparing peptides with untreated control was performed (*p
0.01, **p 0.001).
Harmeier et al. • Glycine 33 of Amyloid- J. Neurosci., June 10, 2009 • 29(23):7582–7590 • 7589
Roher AE, Chaney MO, Kuo YM, Webster SD, Stine WB, Haverkamp LJ,
Woods AS, Cotter RJ, Tuohy JM, Krafft GA, Bonnell BS, Emmerling MR
(1996) Morphology and toxicity of Abeta-(1–42) dimer derived from
neuritic and vascular amyloid deposits of Alzheimer’s disease. J Biol
Chem 271:20631–20635.
RoherAE, Baudry J, ChaneyMO,KuoYM, StineWB, EmmerlingMR (2000)
Oligomerizaiton and fibril asssembly of the amyloid-beta protein. Bio-
chim Biophys Acta 1502:31–43.
Roychaudhuri R, Yang M, Hoshi MM, Teplow DB (2009) Amyloid {beta}-
protein assembly and alzheimer disease. J Biol Chem 284:4749–4753.
Sanner MF, Olson AJ, Spehner JC (1996) Reduced surface: an efficient way
to compute molecular surfaces. Biopolymers 38:305–320.
Sato T, Kienlen-Campard P, Ahmed M, Liu W, Li H, Elliott JI, Aimoto S,
Constantinescu SN, Octave JN, Smith SO (2006) Inhibitors of amyloid
toxicity based on beta-sheet packing of Abeta40 and Abeta42. Biochem-
istry 45:5503–5516.
Schmechel A, Zentgraf H, Scheuermann S, Fritz G, Pipkorn R, Reed J,
Beyreuther K, Bayer TA, Multhaup G (2003) Alzheimer beta-amyloid
homodimers facilitate A beta fibrillization and the generation of confor-
mational antibodies. J Biol Chem 278:35317–35324.
Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini
BL (2007) Natural oligomers of the Alzheimer amyloid- protein in-
duce reversible synapse loss by modulating an NMDA-type glutamate
receptor-dependent signaling pathway. J Neurosci 27:2866–2875.
Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I,
Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM,
Sabatini BL, Selkoe DJ (2008) Amyloid-beta protein dimers isolated di-
rectly from Alzheimer’s brains impair synaptic plasticity and memory.
Nat Med 14:837–842.
Shivaprasad S, Wetzel R (2006) Scanning cysteine mutagenesis analysis of
Abeta-(1–40) amyloid fibrils. J Biol Chem 281:993–1000.
Simmons LK, May PC, Tomaselli KJ, Rydel RE, Fuson KS, Brigham EF,
Wright S, Lieberburg I, Becker GW, Brems DN, Li WY (1994) Second-
ary structure of amyloid beta peptide correlates with neurotoxic activity
in vitro. Mol Pharmacol 45:373–379.
Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT,
Bacskai BJ, Hyman BT (2005) Dendritic spine abnormalities in amyloid
precursor protein transgenic mice demonstrated by gene transfer and
intravital multiphoton microscopy. J Neurosci 25:7278–7287.
Stern EA, Bacskai BJ, Hickey GA, Attenello FJ, Lombardo JA, Hyman BT
(2004) Cortical synaptic integration in vivo is disrupted by amyloid-
plaques. J Neurosci 24:4535–4540.
Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan
MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta pro-
tein potently inhibit hippocampal long-term potentiation in vivo. Nature
416:535–539.
WangHW, Pasternak JF, KuoH, Ristic H, LambertMP, Chromy B, Viola KL,
KleinWL, StineWB, Krafft GA, Trommer BL (2002) Soluble oligomers
of beta amyloid (1–42) inhibit long-term potentiation but not long-term
depression in rat dentate gyrus. Brain Res 924:133–140.
Williams AD, Portelius E, Kheterpal I, Guo JT, Cook KD, Xu Y, Wetzel R
(2004) Mapping abeta amyloid fibril secondary structure using scanning
proline mutagenesis. J Mol Biol 335:833–842.
Williams AD, Shivaprasad S, Wetzel R (2006) Alanine scanning mutagene-
sis of Abeta(1–40) amyloid fibril stability. J Mol Biol 357:1283–1294.
Yankner BA, Dawes LR, Fisher S, Villa-Komaroff L, Oster-Granite ML, Neve
RL (1989) Neurotoxicity of a fragment of the amyloid precursor associ-
ated with Alzheimer’s disease. Science 245:417–420.
Younkin SG (1998) The role of A beta 42 in Alzheimer’s disease. J Physiol
Paris 92:289–292.
Zhao G, Cui MZ, Mao G, Dong Y, Tan J, Sun L, Xu X (2005) gamma-
Cleavage is dependent on zeta-cleavage during the proteolytic processing
of amyloid precursor protein within its transmembrane domain. J Biol
Chem 280:37689–37697.
7590 • J. Neurosci., June 10, 2009 • 29(23):7582–7590 Harmeier et al. • Glycine 33 of Amyloid-
